This inventor holds 3 USPTO granted patents. Top assignee: Roche Palo Alto LLC. Active years: 2009-2015.
Company Filing History:
Years Active: 2009-2015
Title: Joseph Endl: Innovator in Anti-OX40L Antibodies
Introduction
Joseph Endl is a notable inventor based in Wilhelm, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies. With a total of 3 patents to his name, Endl's work focuses on addressing inflammatory diseases through advanced therapeutic solutions.
Latest Patents
One of Endl's latest inventions is related to anti-OX40L antibodies. This invention specifically pertains to anti-OX40L antibodies and variants that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies exhibit new and inventive properties that provide benefits for patients suffering from inflammatory diseases. The innovative nature of these antibodies positions them as a promising avenue for therapeutic intervention.
Career Highlights
Joseph Endl is currently associated with Roche Palo Alto LLC, a leading company in the biotechnology sector. His role at Roche has allowed him to further his research and development efforts in creating effective treatments for inflammatory conditions. Endl's expertise and dedication to his work have made him a valuable asset to the organization.
Collaborations
Throughout his career, Endl has collaborated with several talented individuals, including Martine Van Vugt and Frank Rebers. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of their shared goals in biotechnology.
Conclusion
Joseph Endl's contributions to the field of anti-OX40L antibodies highlight his commitment to improving patient outcomes in inflammatory diseases. His innovative work continues to pave the way for future advancements in biotechnology.